Información del artículo
El Texto completo está disponible en PDF
References
[1.]
A. Herrick.
Pathogenesis of Raynaud's phenomenon.
Rheumatology, 44 (2005), pp. 587-596
[2.]
L. Chung, D. Fiorentino.
Digital ulcers in patients with systemic sclerosis.
Autoimm Rev, 5 (2006), pp. 125-128
[3.]
R. Bakst, J. Merola, A. Franks, M. Sánchez.
Raynaud's phenomenon: pathogenesis and management.
J Am Acad Dermatol, 59 (2008), pp. 633-653
[4.]
J. Korn, M. Mayes, M. Cerinic, M. Rainisio, J. Pope, E. Hachulla, et al.
Digital ulcers in systemic sclerosis prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Art Rheum, 50 (2004), pp. 3985-3993
[5.]
J.R. Lichtenstein.
Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al.
ArtRheum, 48 (2003), pp. 282-283
[6.]
C. Kumana, G. Cheung, C. Lau.
Severe digital ischaemia treated with phosphodiesterase inhibitors.
Ann Rheum Dis, 63 (2004), pp. 1522-1524
[7.]
J. Gore, R. Silver.
Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Ann Rheum Dis, 64 (2005), pp. 1387
[8.]
R. Fries, K. Shariat, H. von Wilmowsky, M. Böhm.
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Circulation, 112 (2005), pp. 2980-2985
[9.]
C. Colglazier, P. Sutej, K. O’Rourke.
Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil.
J Rheumatol, 32 (2005), pp. 2440-2442
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
